Cannabics Pharmaceuticals

99 articles with Cannabics Pharmaceuticals

• Cannabics Pharmaceuticals Announces the Appointment of Dr. Yaakov Waksman as Head of Cannabidiol Research

  12/5/2019

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Dr. Yaakov Waksman is to join the company as Head of Cannabidiol Research.

• Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

  10/16/2019

  Data Demonstrated Cannabics' SR capsules with 5 mg dosage seems to be appropriate for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients under active treatment.

• Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors

  10/7/2019

  Itamar Borochov Joins the Board of Directors Effective Immediately

• Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

  9/12/2019

  Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research data from cannabinoid tests on live cancer biopsies at the 2nd  International Cannabinoid Derived Pharmaceuticals Summit, to be held in Boston, MA

• /C O R R E C T I O N -- issued June 25, 2019 by Cannabics Pharmaceuticals Inc. /

  6/25/2019

  Cannabics Pharmaceuticals Inc. announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

• Cannabics Pharmaceuticals Appoints Two Independent Directors

  6/25/2019

  Cannabics Pharmaceuticals Inc. announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

• Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

  6/4/2019

  Cannabics Pharmaceuticals Inc. announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada.

• Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

  5/30/2019

  Cannabics Pharmaceuticals Inc. announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California.

• Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City

  4/25/2019

  Cannabics Pharmaceuticals Inc. announced that Mr. Eyal Barad, CEO, is scheduled to present at the Planet Microcap Conference in Las Vegas, Nevada, being held at the Bally's Hotel, and at the ThinkEquity Conference in New York City being held at The Mandarin Oriental Hotel.

• Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

  4/17/2019

  Cannabics Pharmaceuticals Inc. announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies.

• SodaStream CEO Daniel Birnbaum to Join Seedo Board

  3/12/2019

  Cannabics Pharmaceuticals Holds Approximately 20% of Seedo

• Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

  3/6/2019

  Companies to Found New Company to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Disorders

• Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

  2/19/2019

  Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies

• Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

  2/7/2019

  Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company

• Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

  2/7/2019

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc.

• Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors

  1/31/2019

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors.

• Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia

  1/24/2019

  Cannabics Pharmaceuticals Inc. announced that NewCanna Hub have signed a non-binding letter of intent at The World Economic Forum, in Davos, Switzerland

• Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos

  1/22/2019

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019. T

• Cannabics Pharmaceuticals to be present during the 37th J.P. Morgan Healthcare Conference In San Francisco

  12/31/2018

  Cannabics Pharmaceuticals Inc. announced that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference.

• Cannabics Pharmaceuticals Announces New Provisional Patent Application for Magnetic Targeting of Cannabinoids

  11/28/2018

  Cannabics Pharmaceuticals (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office.